AR056786A1 - Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com - Google Patents
Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha comInfo
- Publication number
- AR056786A1 AR056786A1 ARP060104898A ARP060104898A AR056786A1 AR 056786 A1 AR056786 A1 AR 056786A1 AR P060104898 A ARP060104898 A AR P060104898A AR P060104898 A ARP060104898 A AR P060104898A AR 056786 A1 AR056786 A1 AR 056786A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- imidazo
- pharmaceutically acceptable
- composite
- pyridin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 1H-imidazo [4,5-c] pyridin-2-yl compound Chemical class 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 150000004677 hydrates Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73595505P | 2005-11-10 | 2005-11-10 | |
| US77228906P | 2006-02-10 | 2006-02-10 | |
| US82692806P | 2006-09-26 | 2006-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056786A1 true AR056786A1 (es) | 2007-10-24 |
Family
ID=38049129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104898A AR056786A1 (es) | 2005-11-10 | 2006-11-08 | Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100056523A1 (https=) |
| EP (1) | EP1948188A4 (https=) |
| JP (1) | JP2009516653A (https=) |
| KR (1) | KR20080067646A (https=) |
| AP (1) | AP2008004442A0 (https=) |
| AR (1) | AR056786A1 (https=) |
| AU (1) | AU2006315805A1 (https=) |
| BR (1) | BRPI0618309A2 (https=) |
| CA (1) | CA2629429A1 (https=) |
| EA (1) | EA200801301A1 (https=) |
| EC (1) | ECSP088425A (https=) |
| IL (1) | IL190968A0 (https=) |
| MA (1) | MA29935B1 (https=) |
| NO (1) | NO20082414L (https=) |
| TW (1) | TW200736260A (https=) |
| WO (1) | WO2007058850A2 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090227616A1 (en) * | 2005-11-10 | 2009-09-10 | Smithkline Beecham Corporation, A Corporation | Inhibitors of akt activity |
| DK2240781T3 (en) | 2008-01-18 | 2018-03-26 | Harvard College | METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| JP2011521214A (ja) * | 2008-05-16 | 2011-07-21 | セルゾーム アーゲー | Ｐａｒｐ相互作用分子の同定およびｐａｒｐタンパク質の精製のための方法 |
| AU2009263037B2 (en) * | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| ES2663222T3 (es) | 2008-12-19 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina útiles como inhibidores de la quinasa ATR |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP5856151B2 (ja) | 2010-05-12 | 2016-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体 |
| JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピラジン |
| US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| EP2596134B1 (en) * | 2010-07-23 | 2020-04-08 | President and Fellows of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| MX2013010513A (es) * | 2011-03-16 | 2013-10-07 | Hoffmann La Roche | Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos. |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| KR20140084112A (ko) | 2011-09-30 | 2014-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| WO2013049859A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| ES2909438T3 (es) | 2013-06-26 | 2022-05-06 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Enantiómero (S) de mepacina como inhibidor de paracaspasa (MALT1) para tratar cáncer |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| TWI627173B (zh) * | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
| PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| AU2015334917B2 (en) | 2014-10-23 | 2019-08-29 | Janssen Pharmaceutica Nv | New compounds as NIK inhibitors |
| JP6616412B2 (ja) | 2014-10-23 | 2019-12-04 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新規のピラゾロピリミジン誘導体 |
| BR112017008039B1 (pt) | 2014-10-23 | 2023-04-11 | Janssen Pharmaceutica N.V. | Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende |
| MX371151B (es) | 2014-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| JP2022512706A (ja) | 2018-10-16 | 2022-02-07 | エフ．ホフマン－ラ ロシュ アーゲー | 眼科におけるＡｋｔ阻害剤の使用 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |
| WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
| EP4615431A1 (en) | 2022-11-11 | 2025-09-17 | Astrazeneca AB | Combination therapies for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045134A1 (es) * | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
-
2006
- 2006-11-08 TW TW095141228A patent/TW200736260A/zh unknown
- 2006-11-08 AR ARP060104898A patent/AR056786A1/es unknown
- 2006-11-09 AP AP2008004442A patent/AP2008004442A0/xx unknown
- 2006-11-09 WO PCT/US2006/043513 patent/WO2007058850A2/en not_active Ceased
- 2006-11-09 CA CA002629429A patent/CA2629429A1/en not_active Abandoned
- 2006-11-09 EA EA200801301A patent/EA200801301A1/ru unknown
- 2006-11-09 BR BRPI0618309-3A patent/BRPI0618309A2/pt not_active Application Discontinuation
- 2006-11-09 KR KR1020087011158A patent/KR20080067646A/ko not_active Withdrawn
- 2006-11-09 JP JP2008540168A patent/JP2009516653A/ja active Pending
- 2006-11-09 US US12/093,032 patent/US20100056523A1/en not_active Abandoned
- 2006-11-09 AU AU2006315805A patent/AU2006315805A1/en not_active Abandoned
- 2006-11-09 EP EP06837170A patent/EP1948188A4/en not_active Withdrawn
-
2008
- 2008-04-17 IL IL190968A patent/IL190968A0/en unknown
- 2008-05-05 MA MA30904A patent/MA29935B1/fr unknown
- 2008-05-05 EC EC2008008425A patent/ECSP088425A/es unknown
- 2008-05-28 NO NO20082414A patent/NO20082414L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080067646A (ko) | 2008-07-21 |
| NO20082414L (no) | 2008-08-05 |
| EP1948188A4 (en) | 2011-02-16 |
| TW200736260A (en) | 2007-10-01 |
| US20100056523A1 (en) | 2010-03-04 |
| EA200801301A1 (ru) | 2009-02-27 |
| EP1948188A2 (en) | 2008-07-30 |
| MA29935B1 (fr) | 2008-11-03 |
| WO2007058850A3 (en) | 2009-04-30 |
| ECSP088425A (es) | 2008-06-30 |
| AP2008004442A0 (en) | 2008-04-30 |
| AU2006315805A1 (en) | 2007-05-24 |
| JP2009516653A (ja) | 2009-04-23 |
| CA2629429A1 (en) | 2007-05-24 |
| IL190968A0 (en) | 2009-02-11 |
| BRPI0618309A2 (pt) | 2011-08-23 |
| WO2007058850A2 (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056786A1 (es) | Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com | |
| AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
| RU2009113615A (ru) | Ингибитор киназы | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| CY1116688T1 (el) | Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων | |
| KR101575706B1 (ko) | 암 치료용 선택적인 ｅｐ４ 수용체 길항제 | |
| KR20180037228A (ko) | 항박테리아 치료제 및 예방제 | |
| AU2013269809B2 (en) | Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients | |
| MX2009006474A (es) | Derivados de benzamida como agonistas del receptor ep4. | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| BRPI0415053B8 (pt) | inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
| JP2009539994A5 (https=) | ||
| JP5345842B2 (ja) | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| DE60120962D1 (de) | Substituierte chalkone als arzneimitteln | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| BR112017016883B1 (pt) | Compostos com atividade antitumoral | |
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |